Avalo Therapeutics (AVTX) Gains from Investment Securities (2014 - 2026)
Avalo Therapeutics (AVTX) reported Gains from Investment Securities of $779000.0 for Q1 2026, up 102.16% quarter-over-quarter from -$36.0 million in Q3 2024.
Avalo Therapeutics (AVTX) Gains from Investment Securities (2014 - 2026) Analysis & Trends
Avalo Therapeutics has reported Gains from Investment Securities for 10 years, with the latest figure at $779000.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities changed N/A year-over-year to $779000.0; the trailing twelve-month figure through Mar 2026 stood at $779000.0 (up 100.53% YoY), and the FY2025 full-year result was $510000.0, changed N/A from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $779000.0, up from -$36.0 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $1.7 billion in Q4 2022, with the low at -$112.0 million in Q2 2024.
- Historically, Gains from Investment Securities has averaged $326.4 million across 3 years, with a median of $779000.0 in 2026.
- The largest YoY upside for Gains from Investment Securities was 170100.0% in 2022 against a maximum downside of 170100.0% in 2022.
- Avalo Therapeutics' Gains from Investment Securities stood at $1.7 billion in 2022, then sank by 102.12% to -$36.0 million in 2024, then soared by 102.16% to $779000.0 in 2026.
- The last three Gains from Investment Securities figures came in at $779000.0 (Q1 2026), -$36.0 million (Q3 2024), and -$112.0 million (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Avalo Therapeutics | 295.77 Mn | 295.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 779,000.00 |
| Mar 31, 2026 | 779,000.00 |
| Sep 30, 2024 | -36.03 Mn |
| Sep 30, 2024 | -36.03 Mn |
| Jun 30, 2024 | -112.05 Mn |
| Jun 30, 2024 | -112.05 Mn |
| Mar 31, 2024 | 79.28 Mn |
| Mar 31, 2024 | 79.28 Mn |
| Dec 31, 2022 | 1.70 Bn |
| Dec 31, 2022 | 1.70 Bn |
| Dec 31, 2021 | -1.00 Mn |
| Dec 31, 2021 | -1.00 Mn |
| Sep 30, 2021 | 2.00 Mn |
| Sep 30, 2021 | 2.00 Mn |
| Dec 31, 2020 | -376,000.00 |
| Dec 31, 2020 | -376,000.00 |
| Jun 30, 2020 | 376,000.00 |
| Jun 30, 2020 | 376,000.00 |
| Dec 31, 2019 | -1.00 |
| Dec 31, 2019 | -1.00 |